KOBE Study of Pioglitazone Effective in Preventing Restenosis after Endovascular Therapy

Trial Profile

KOBE Study of Pioglitazone Effective in Preventing Restenosis after Endovascular Therapy

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 14 May 2016

At a glance

  • Drugs Pioglitazone (Primary) ; Antihyperglycaemics
  • Indications Restenosis; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms KOBE-SPEED
  • Most Recent Events

    • 14 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top